



HYPERTENSION CANADA

2025 ANNUAL REPORT

☎ (905) 943-9400

✉ info@hypertension.ca

🌐 <https://hypertension.ca/>



TABLE OF CONTENTS

President's Report	2
Executive Director's Report	4
About Hypertension Canada	5
Strategic Plan 2025-2028	6
Board of Directors	7
Committees	11
Awards Committee	11
Canadian Hypertension Coalition	12
Canadian Hypertension Congress Committee	12
Device Recommendation Program Committee.....	13
Education and Implementation Committee	13
Finance Committee	14
Governance Committee	14
Guidelines Committee	15
Membership Committee	15
Research and Evaluation Committee	16
2025 Financial Overview	17
Staff	18

PRESIDENT'S REPORT

I am pleased to present a review of Hypertension Canada's accomplishments in 2025, a year marked by strategic reflection, activities to strengthen the organization, and continued delivery on our mission.

Update on 2022-2024 Strategic Plan:

Over the past year, Hypertension Canada primarily focused on four core areas, each contributing to our mission and furthering the 2022-2024 strategic goal to "be the trusted voice for hypertension and cardiovascular risk":



1. Canadian Hypertension Congress

Member education remained a priority in 2025. The 2025 Canadian Hypertension Congress was held virtually on May 29–30, with 128 registrants participating. The program featured nine scientific sessions delivered by ten presenters and was supported by Medtronic and A&D Medical.

Planning for the 2026 Congress is underway, with the Congress Committee actively preparing for an in-person meeting. Further details will be shared with members in the coming months!

2. Guidelines

Significant progress was made on the new Hypertension Canada Guidelines, which are being developed using a two-part approach:

- **The Primary Care Guideline**, designed to support practical implementation in frontline care, was published in CMAJ in May 2025. As of the writing of this report, the primary care guideline remains one of the most frequently viewed articles on the CMAJ site.
 - We were especially proud that a patient/public guideline is included as one of the appendices to the Primary Care Guideline, developed in close partnership with several patient and public representatives and designed to clearly and simply share key messaging from the new Primary Care Guideline as a tool to improve health.
- **The Comprehensive Guideline**, intended for more specialized practice, will be a living guidelines framework with the launch of the first topics planned for 2026. The Comprehensive Guidelines are being developed by our Guidelines Committee and in collaboration with Hypertension Australia, strengthening international partnerships and reinforcing our shared commitment to advancing cardiovascular health

This work reflects the dedication of our volunteers, committees, and partners to ensuring hypertension care remains evidence-based, accessible, and relevant.

3. Governance Renewal, Strategic Planning and Operations

As part of an ongoing focus on good governance, Hypertension Canada participated in the Canadian Society of Association Executives (CSAE) Symposium, helping ensure our organizational structures and leadership practices remain aligned with national standards for non-profit associations.

The Governance Committee and Board of Directors also had a busy year, reviewing and updating many of our operational policies and committee Terms of Reference – all as part of this drive to solidify and document organizational structures and key governance frameworks.

The Board of Directors held six regular Board meetings this year in addition to a dedicated strategic planning workshop. The two-day meeting resulted in our new strategic plan and re-oriented priorities to guide Hypertension Canada in the years ahead. We are grateful to the many contributors who shared their perspectives and expertise throughout this process, and we look forward to advancing the vision and goals established through this work. I would like to sincerely thank our Board members for the time, energy, and insight they bring to Hypertension Canada. Your commitment to strong governance and to our mission is invaluable.

This past year, Hypertension Canada also made the difficult decision to change management companies. A formal request for proposals (RFP) was issued, and after a comprehensive review and interview process, BUKSA Conferences + Associations was selected as our new association management partner, with the transition to the new management team beginning September 1, 2025. This partnership will enhance operational capacity and strengthen services for members and volunteers.

4. Strategic Planning for 2025-2028:

In September, the Hypertension Canada Board of Directors, the new management team, and a curated group of volunteers and stakeholders convened in Calgary for two days of intensive strategic planning. The purpose of the meeting was to redefine the mission, vision and values of Hypertension Canada to better align with the association's areas of focus; to clarify and define the member communities that we serve and the value propositions and structures needed to deliver on that value; and to chart a practical path forward to increase our visibility and impact.

The outcomes of the strategic planning sessions were a refreshed mission and vision, along with new values and strategic pillars from which the organization has mapped out a series of concrete goals. We're excited to share the new strategic plan here for the first time.

My first year as President has been both rewarding and energizing, as Hypertension Canada continues to refresh and renew its organizational focus. I am deeply grateful for the support of the Board, our members, volunteers and partners as we strengthen and grow the organization. As always, our work depends on the commitment of dedicated volunteers, and I encourage members to consider becoming involved.

Laurel Taylor

Respectfully submitted,
Laurel Taylor



EXECUTIVE DIRECTOR'S REPORT



It is a privilege to serve as Executive Director of Hypertension Canada, a role I assumed in September 2025. I am grateful for the opportunity to work alongside a dedicated Board, committed volunteers, and an enthusiastic management team – and I am energized by the chance to bring a fresh perspective and renewed focus to support the organization's mission.

2025 was a year of continued momentum and transition for Hypertension Canada, even before our team took the helm. Key activities included successful delivery of the virtual Canadian Hypertension Congress, renewed terms of reference and policies to guide organizational activities, meaningful progress on the updated Guidelines and launch of the Primary Care Guideline, and the development of the 2025-2028 Strategic Plan, which maps out tangible actions to ensure continued visibility and elevate the impact of Hypertension Canada's work to advance our mission and vision.

Updates on Key Activities:

a. Canadian Hypertension Congress

- 128 attendees participated in the two-day Virtual Congress this past year
- \$16,500 in sponsorship support was confirmed, from Medtronic and A&D
- Virtual Congress costs were significantly lower than for previous in-person meetings and as a result, the overall program budget resulted in only a modest deficit, in keeping with the commitment to provide opportunities for member education and engagement.

c. HC Device Recommendation Program

- Revenue of \$279,879 in the 2025 fiscal year
- 10 devices were reviewed by the Committee during the fiscal year (with our thanks), in addition to 33 equivalencies

b. Hypertension Canada – Professional Certification Program (HC-PCP)

- Registrations to date: 258 (full program), Level 1: 91, Level 2: 7
- New registrations in 2025: 40 (full program) and 9 for Level 1 only
- Total of \$314,834 in revenue to date, and \$33,402 in the 2025 fiscal year
- Total of 16 graduates in 2025

d. Membership

- Hypertension Canada memberships continue to offer good value, with overall member numbers in 2025 remaining largely consistent relative to the previous year 2025

Looking ahead, I am focused on advancing Hypertension Canada's strategic priorities, continuing to strengthen operational foundations and financial health, and ensuring the organization is well-positioned to deliver value to members, partners, and the broader health system. I look forward to building on the strong work already underway and contributing to the next phase of Hypertension Canada's evolution alongside the dedicated members of our Board of Directors and Committees.

Thank you for all that you do to support our mission!

A handwritten signature in black ink, appearing to read 'Maureen Melnyk', with a stylized flourish at the end.

Maureen Melnyk, BA (Hons), MA
Executive Director



ABOUT HYPERTENSION CANADA

Our vision: Healthy Blood Pressure. Better Lives. Every Person

Our mission: Hypertension Canada is the only national organization solely dedicated to the prevention, detection, and control of high blood pressure and its complications – to improve cardiovascular health for all.

We deliver on our mission and vision by focusing on the following **strategic pillars**, the core areas where we see our greatest impact:

- Membership and Stakeholder Engagement
- Research and Community Building
- Partnership and Advocacy
- Knowledge Mobilization
- Capacity Building

And we do it all by aligning our activities with the following **values**:

- *Evidence: We base everything we do in science*
- *Knowledge Mobilization: We share and mobilize the knowledge generated*
- *Collaboration and Partnership: We work with others to create impact*
- *Impact and Advocacy: We amplify our voices to improve health outcomes*
- *Equity, Diversity and Inclusion: We strive to include everyone*

Seven and a half million people in Canada, about 1 in 4 adults, live with hypertension. Hypertension is also the single most important risk factor for premature death and disability in the world. Canada has become an international leader in the early detection of high blood pressure, its treatment, and overall management. With over 40 years and a strong membership of dedicated volunteers and professionals, Hypertension Canada will continue our work to prevent, detect and control high blood pressure to improve cardiovascular health for all.

STRATEGIC PLAN 2025-2028

Strategic Plan Priorities:

1. Mobilize the Primary Care Guidelines to broaden public awareness and health care provider uptake.
2. Expand the visibility and impact of the device recommendation program.
3. Increase Hypertension Canada membership.
4. Build and foster partnerships with other organizations so that Hypertension Canada is seen as a connector and facilitator of collaboration and advocacy.



BOARD OF DIRECTORS

2025-2026



Dr. Laurie K. Taylor,
BSc, MBA, PhD
President

Dr. Laurel Taylor is currently the Corporate Director, Quality, Patient Safety & Experience at Covenant Health, which provides programs and services across the province of Alberta. Her educational background includes completion of a BSc (Eng), an MBA and a PhD (Business). Following several years as an engineer in the oil and gas sector, her MBA led her to a position in healthcare administration. Following completion of her doctoral program at the University of Alberta, Laurie went on to complete a post-doctoral fellowship at McGill University. She also completed the Harkness Fellowship in Health Policy with The Commonwealth Fund. Previous leadership positions at the Canadian Patient Safety Institute, the Canadian Institutes of Health Research and Alberta Health Services contribute to Laurie's commitment and expertise to foster the mission and vision of Hypertension Canada.



Dr. Mohsen Agharazii
Vice President

Dr. Mohsen Agharazii is a professor of medicine at Université Laval, a nephrologist, and the director of the Endocrinology-Nephrology research axis at the CHU de Québec Hospital in Quebec City. He has done his medical training at Université Laval, followed by research training in Paris at HEGP and Manhès Hospital under the supervision of Professors Stéphane Laurent, Pierre Boutouyrie and Gérard London.

Over the past decade, he has developed his research program, which focuses on the mechanisms of large artery remodelling in the context of CKD, both in humans and in animal models. His research has been supported by the Canadian Institute of Health Research, Kidney Foundation of Canada, and Heart and Stroke Foundation and the Canadian Foundation for Innovation. He has received research scholarships from Fonds de recherche du Québec – Santé, and he has been awarded the Université Laval-Amgen Research Chair in nephrology. He is currently the president of the Société Québécoise d'Hypertension Artérielle (2022-2024), and he is the author or co-author of 95 peer-reviewed articles in the field of nephrology and hypertension.



Dr. Ross T. Tsuyuki,
BSc(Pharm), PharmD, MSc,
FCSHP, FACC, FCAHS, ISHF
Past-President

Dr. Ross Tsuyuki is a Professor of Medicine (Cardiology) and Director of the EPICORE Centre (a health research coordinating centre) at the University of Alberta and is the Editor-in-Chief of the Canadian Pharmacists Journal. Having previously served on Hypertension Canada's Board of Directors, Dr. Tsuyuki was president from 2020-2024. He also served as Chair of the Knowledge Mobilization Committee and is a member of the Hypertension Canada Guidelines Committee.

Dr. Tsuyuki's interests are in clinical trials design and execution, hypertension, heart failure, community practice-based research, cardiovascular risk factors, and the provision of support for clinical researchers through the EPICORE Centre.

Dr. Tsuyuki has received several awards for teaching, as well as an appointment as a Fellow of the Canadian Society of Hospital Pharmacists, the American College of Cardiology, the Canadian Academy of Health Sciences, and the International Society of Hypertension. In 2005, he was recognized as the Canadian Pharmacist of the Year by the Canadian Pharmacists Association and the International Society of Hypertension.



Mr. Paul Braconnier
Treasurer

Paul Braconnier is a retired financial professional with decades of accounting and project management skills.

After spending 10 years with Ernst & Young, with his later years as a Senior Audit Manager and Computer Audit Specialist, he spent the next ten years as controller and chief financial officer in several organizations, where he continued to hone his financial and project management skills.

In 2000, Paul co-founded a clinical contract research organization (CRO) that assisted pharmaceutical and biotechnology companies in carrying out human clinical trials, ranging from small Phase I studies with a dozen patients to large Phase III studies with upwards of 2,000 patients.

In 2012, after having divested the operations of the CRO, Paul joined TEC Edmonton as an Executive-In-Residence. TEC Edmonton was a joint venture between the University of Alberta and the City of Edmonton, created to assist in the commercialization of technologies invented at the University of Alberta and at the City of Edmonton. He spent two years assisting various constituencies in these organizations to streamline their operations and commercialize their technologies.

Having retired in 2014, Paul and his spouse travel and volunteer in various capacities and Paul continues to advise former clients and colleagues on various financial and technology issues in a volunteer capacity.



Dr. Jill Bruneau,
BScN, MHS, PhD
Director

Dr. Jill Bruneau is currently an Associate Professor and Nurse Practitioner (NP) Coordinator for the Master of Science in Nursing Program, NP Option at Memorial University in Newfoundland and Labrador. Jill is a PhD-prepared nurse practitioner with experience caring for cardiac patients over the past 20 years and educating NP students for over 12 years. Her dissertation work was focused on cardiovascular health promotion and the development and testing of an intervention for the early detection of cardiac risk factors and management of patients by health care providers using evidence-based guidelines. Jill has attained numerous scholarships and research grants for her dissertation work and current research initiatives. Jill is currently working on her program of research in the areas of knowledge translation, cardiovascular health promotion, management of risk factors, and timely access of vulnerable groups to appropriate health care services.

In 2018-2019, Jill participated in the Hypertension Canada Task Force Committee with other leaders within the HC community. In 2013, she was the recipient of the Hypertension Canada Certificate of Excellence Award, nominated by Lynn Cloutier, PhD, RN, for her extension work in educating students, both undergraduate and graduate students, through guest lectures about hypertension management and prevention. Jill has also participated in various public engagement events promoting effective hypertension management and distributing the excellent materials published by HC. Jill was involved in publishing an article in *The Canadian Nurse* about the importance of bringing focus to hypertension and another publication for the *Canadian Journal of Cardiovascular Nursing* about the WHO celebrating World Health Day on April 7, 2013, focusing on hypertension. Jill has been a Hypertension Canada member with regular attendance at the annual HTN Congress for about a decade and, in recent years; have attended through a virtual platform.



Dr. Shelita Dattani,
Bsc.Pharm., Pharm.D
Director

Dr. Shelita Dattani is the Vice President of Pharmacy Affairs at the Neighbourhood Pharmacy Association of Canada, where she leads a team advocating for pharmacy's evidence-based role in delivering accessible, high-quality healthcare and building capacity in public health and primary care.

Sheli received her Bachelor of Science in pharmacy from Northeastern University and her Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill. Sheli is a pharmacist with over 20 years of experience in various sectors of the profession, including community, hospital, academia, industry, group purchasing organizations, and professional and pharmacy associations.

Sheli maintains a part-time practice in primary care team-based care, community pharmacy, and remote hospital telepharmacy. Sheli also serves as a lecturer at The Memorial University of Newfoundland and as a guest lecturer at The University of Waterloo in their Doctor of Pharmacy Programs. She is passionate about her continued engagement as a preceptor, teacher, and educator, and draws inspiration from her roles in supporting students and pharmacists in their professional development. Sheli is committed to contributing to the pharmacy's growing role as an integral health care partner.



Ms. Kerri Eady,
BA, Hons.
Director

Kerri Eady is currently the Director of Sales and Marketing for Cambridge Brass Inc. Kerri holds a Hons Degree in Managerial Economics from the University of Guelph and her Business Coaching Certification. She is currently pursuing further education in Leadership Coaching and Group Dynamics, as well as her Project Management Certification through PMI. Prior to Cambridge Brass, Kerri was the General Manager and Director of Sales for Gemini, Inc., a custom branding and signage solutions manufacturer throughout North America. With nearly 25 years of leadership experience in consumer industries, she has a practiced skill set in marketing and operations strategy, branding and communications, as well as training and policy creation, being accountable to divisional oversight in multinational organizations. Kerri currently prioritizes her professional time with industry and community volunteer positions, earning her the 2021 Volunteer of the Year and 2022 Mentor of the Year with the Sign Association of Canada.



Mr. David G. Henley,
KC.
Director

David Henley is currently part-time Counsel to Irving Shipbuilding, providing support for key legal issues. Previously, he was the Vice President and General Counsel at Irving Shipbuilding from 2015 to 2019 and General Counsel for Acadian Seaplants Limited from 2020 to 2022. From 2001 to 2015, he was a partner in the Halifax office of Stewart McKelvey, where he had a broad, commercially oriented practice in maritime, construction, energy and natural resources, and environmental law.

Before law, David had a career in the army as an artillery officer. He continued to serve in the Army Reserve while practicing law, and after returning from a tour in Afghanistan in 2010 was invested as a member of the Order of Military Merit by the Governor-General. He retired from the Army in 2015 as a Brigadier-General after 30 years of full and part-time service. His last position was Deputy Commander for the 5th Canadian Division, essentially the Army in Atlantic Canada.

He has written, presented and published papers and contributed to books on various marine and environmental subjects. David was a member of the part-time faculty at the Schulich School of Law, where he taught Fisheries Law from 2004 to 2015. He was a member of the Transportation Appeal Tribunal of Canada from 2010 to 2017. In addition to the board of Hypertension Canada, David currently serves on the board for the Chronic Pain Centre of Excellence for Veterans and was on the board for the Halifax Citadel Society from 2017 to 2025.

HYPERTENSION CANADA COMMITTEES

Hypertension Canada's committees support the Board of Directors by providing expertise, analysis and guidance across key areas of the organization's work. Through their leadership and volunteer contributions, committees play a vital role in advancing Hypertension Canada's mission and strategic priorities. Members interested in joining a committee are encouraged to contact the office at info@hypertension.ca

AWARDS COMMITTEE



The Awards Committee supports the Board of Directors by overseeing the annual recognition awards selection process. The Committee reviews submitted nominations and evaluates them against established awards policies and criteria.

Members of the 2025 Committee:

- Dr. Remi Goupil (Chair)
- Ms. Joy Akhiwu
- Dr. Dylan Burger
- Dr. Pavel Hamet
- Dr. Donna McLean
- Ms. Mariane Bertagnolli

Update on Previous Activities, Accomplishments, and Initiatives:

- Last year's winners: France Boulianne (Certificate of Excellence), Vanessa Zanelle and Tom MacMillan (Hypertension Innovations Award), Rahul Chanchlani (Jacques de Champlain New Investigator Award), Stella Daskalopoulou (Senior Investigator Award)
- In the Fall, the first announcement for the 2026 awards was launched.



CANADIAN HYPERTENSION COALITION



The Canadian Hypertension Coalition serves as Hypertension Canada's advocacy arm, bringing together healthcare organizations to prioritize actions for the prevention and control of hypertension. Through coordinated advocacy efforts, the Coalition engaged with government to advance policies that support the health of the 7.5 million Canadians living with hypertension.

Members of the 2025 Executive Committee:

- Dr. Kara Nerenberg
- Dr. Laurel Taylor
- Dr. Norm Campbell
- Manny Arango
- Dr. Sachin Pasricha
- Ms. Patrice Lindsay
- Dr. Shelita Dattani

Update on Previous Activities, Accomplishments, and Initiatives:

- The Coalition met in 2025 to review previous activities and engaged in a priority-setting exercise, including a feedback survey, to solicit recommendations on future avenues for advocacy and health promotion
- Coalition Chair Dr. Kara Nerenberg was part of the 2025-2028 Strategic Planning workshop, providing input on activities where Hypertension Canada could have greatest impact, either as part of the Coalition or working in tandem with other partners

Next Steps and Focus for Next 6 Months:

- Renewal and expansion of Coalition membership
- Review of Coalition Terms of Reference
- Development of a plan for key areas of impact and priority activities

CANADIAN HYPERTENSION CONGRESS COMMITTEE



The Canadian Hypertension Congress Committee sets the strategic direction and guides the planning of Hypertension Canada's annual scientific congress – the only national meeting dedicated exclusively to hypertension. The Committee works to strengthen the Congress's scientific quality, relevance, and value to enhance engagement, attendance, and sustainability.

Members of the 2025 Committee:

- Dr. Dylan Burger (Co-Chair)
- Dr. Kristin Terenzi (Co-Chair)
- Dr. Sachin Pasricha
- Dr. Ross Tsuyuki
- Dr. Gemma Cheng
- Dr. Joanne Arcand
- Dr. Noriko Daneshtalab
- Dr. Julie Lavoie
- Dr. Paula Harvey
- Ms. Dorothy Morris
- Dr. Swapnil Hiremath
- Keila Turino Miranda
- Dr. Rhian Touyz
- Dr. Rahul Chanchlani
- Ms. Joy Akhiwu

Update on Previous Activities, Accomplishments, and Initiatives:

- The 2025 Canadian Hypertension Congress was held virtually from May 29-30, 2025
- The Congress amassed a total of 128 participants joining 10 talks over two days
- Two industry sponsors supported the event: Medtronic and A&D Medical
- A total of \$16,500 in sponsorship revenue was collected

Next Steps and Focus for Next 6 Months:

- Planning of the 2026 in-person Congress
- Revised package of sponsor levels and benefits, to increase support for Hypertension Canada's educational activities, including but not limited to the Congress
- Renewal and expansion of committee membership

DEVICE RECOMMENDATION PROGRAM COMMITTEE

.....

Hypertension Canada's Device Recommendation Program supports Canadians, healthcare providers, and organizations in making informed purchasing decisions for home, clinical, and ambulatory blood pressure measurement devices. The program promotes the use of properly validated devices recommended by Hypertension Canada, helping to improve the accuracy and reliability of blood pressure measurement.

Members of the 2025 Committee:

- Dr. Swapnil Hiremath (Chair)
- Dr. Ross Tsuyuki
- Dr. Remi Goupil
- Dr. Karen Tran
- Dr. Sachin Pasricha
- Dr. Lisa Dubrofsky

Update on Previous Activities, Accomplishments, and Initiatives:

- The program continues to contribute positively to the HC mission, with two Committee meetings in the last year discussing how to expand enrollments, increase program visibility, and provide education around the importance of using endorsed devices
- Ten new devices were reviewed or are currently under review by the Committee, in addition to a formidable thirty-three equivalency assessments

Next Steps and Focus for Next 6 Months:

- Design a webinar around device validation
- Expand validation efforts to include cuffless devices and explore options for validating devices specifically for use in pregnancy

EDUCATION AND IMPLEMENTATION COMMITTEE

.....

The Education and Implementation Committee advances Hypertension Canada's role as a trusted national hypertension resource by developing and supporting education and implementation initiatives that promote uptake of Hypertension Canada guidelines. Late in 2025, to reflect our revised mission and vision – and recognizing that knowledge mobilization is a key organizational value and strategic pillar – the committee was rebranded as the Knowledge Mobilization Committee, with broad responsibility for all activities that advance mobilization of the collective expertise of our members.

Members of the 2025 Committee:

- Dr. Maoliosa (Mo) Donald (Chair)
- Dr. Laurel Taylor
- Dr. Remi Goupil
- Dr. Greg Hundemer
- Dr. Ross Tsuyuki
- Dr. Shelita Dattani

Update on Previous Activities, Accomplishments, and Initiatives:

- With the roll-out of the 2025 Primary Care Guideline and anticipating the first Comprehensive Guidelines topics to be launched in the coming year, the Committee focused on guidelines implementation and broader knowledge mobilization activities to ensure Hypertension Canada delivers on its strategic goals.
- Dr. Maoliosa Donald (University of Calgary) has assumed leadership of the Committee with this new mandate.
- Initial activities included publications in CMAJ, CPJ, and CFP; a press release and media interview; conference presentations; initial outreach to provincial healthcare professional associations; and Hypertension Canada-hosted English and French webinars in June.

Next Steps and Focus for the Next 6 Months:

- Spearhead a revitalized webinar series
- Support the translation and dissemination of new guidelines for priority populations and settings
- Launch refreshed educational materials to support guideline uptake

FINANCE COMMITTEE

Hypertension Canada's Finance Committee assists the Board in providing financial analysis, advice, and oversight of the organization's budget. The Finance Committee regularly reviews the quarterly and annual financial statements and provides recommendations to ensure Hypertension Canada's financial health.

Members of the 2025 Committee:

- Mr. Paul Braconnier (Chair)
- Mr. Trevor Hudson
- Mr. David Henley
- Mr. Henry Lee
- Dr. John Floras



GOVERNANCE COMMITTEE

The Governance Committee is a standing committee of the Board of Directors responsible for recommending committee structure and composition, Board nominations, and standing committee appointments. The Committee also supports effective governance, overseeing the review and development of policies, processes, and bylaw revisions.

Members of the 2025 Committee:

- Dr. Laurie Taylor (Chair)
- Ms. Dorothy Morris
- Mr. David Henley

Update on Previous Activities, Accomplishments, and Initiatives:

- The Governance Committee met three times during the past year.
- The Governance Committee continues to monitor vacant and soon-to-be-vacant Board positions, ensuring Board member profiles are kept up to date to maintain an appropriate mix of competencies available on the Board.
- The following policies were reviewed and updated as appropriate:
 - Privacy Policy
 - Conflict of Interest Policy
 - Nominations Policy
 - Investment Policy
 - Attendance Policy
- The Terms of Reference were reviewed for the following Committees, with revisions recommended to the Board:
 - Guidelines Committee
 - Research and Evaluation Committee
 - Education and Implementation Committee
 - Awards Committee
 - Device Recommendation Committee

Next Steps and Focus for the Next 6 Months:

- Complete outstanding policy reviews

GUIDELINES COMMITTEE



The Guidelines Committee oversees the development of Hypertension Canada's clinical practice guidelines and promotes innovation in guideline methodology and content to support high-quality hypertension care.

Members of the 2025 Executive Committee:

- Dr. Gregory Hundemer (Co-Chair)
- Dr. Remi Goupil (Co-Chair)
- Dr. Ross Tsuyuki
- Dr. Kristen Terenzi
- Dr. Nancy Santesso
- Ms. Kerri Eady

Update on Previous Activities, Accomplishments, and Initiatives:

- The Primary Care Guideline was published in May/June 2025 and received more than 40,000 views on the CMAJ website, with the printed version released in September
- Knowledge mobilization efforts continued, including the development of a new Knowledge Mobilization Committee to support guideline implementation

Next Steps and Focus for the Next 6 Months:

- Explore innovative approaches to systematic reviews to accelerate guideline development while maintaining methodological rigour
- Advance guideline work in priority topic areas, including:
 - Primary aldosteronism
 - Pediatrics, adolescence, and young adulthood
 - Pregnancy and post-partum care
 - Care of the frail elderly

MEMBERSHIP COMMITTEE



The Membership Committee is a standing committee of the Board of Directors that supports the Board's oversight of membership reporting, policies, and strategies. The Committee focuses on strengthening member engagement, recruitment, and retention in support of Hypertension Canada's long-term sustainability.

Members of the 2025 Committee:

- Mr. Reid McDonald (Chair)
- Dr. Laurel Taylor
- Dr. Jill Bruneau
- Dr. Dylan Burger
- Dr. Jonathan Gabor
- Keila Turino Miranda

Update on Previous Activities, Accomplishments, and Initiatives:

- Current Membership is sitting at 132 members
- Met three times since the last AGM report
- The committee was focused on discussing member value and segments

Next Steps and Focus for the Next 6 Months:

- Finalize updated Member Value Propositions and present a slate of proposed member benefit enhancements to the Board for approval before the 2026 membership renewal campaign
- Reid McDonald will step back as Chair in mid-2026

RESEARCH AND EVALUATION COMMITTEE

.....

The Research and Evaluation Committee advances hypertension research with a focus on ongoing surveillance of key indicators, including prevalence, awareness, treatment, and control. The Committee supports and empowers healthcare professionals to engage in hypertension screening and management, leads Canadian participation in the annual May Measurement Month blood pressure screening campaign, and provides ad hoc research support aligned with the work of the Guidelines and Knowledge Mobilization Committees.

Members of the 2025 Committee:


- Dr. Alexander Leung (Co-Chair)
- Dr. Stephanie Gysel (Co-Chair)

Update on Previous Activities, Accomplishments, and Initiatives:

- Update of hypertension key indicators in Canadian adults using cycle 6 of the Canadian Health Measures Survey (CJC Open. 2024 May 29;6(9):1099-1107).
- Estimation of potential impact of inaccurate BP measurement from non-validated BP devices in Canada (CJC Open. 2024 Nov 8;7(2):239-246).
- HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary care. (Rev Panam Salud Publica. 2025 Apr 18;49:e35.)
- A hyper-opportunity for pharmacy. Can Pharm J (Ott). 2025 May 29;158(4):183-185.
- Community pharmacy-based hypertension screening: May Measurement Month 2023 in 3 Canadian provinces. Can Pharm J (Ott). 2025 Jan 24;158(2):77-80.
- Acceptability of hypertension screening in pharmacies participating in May Measurement Month. Can Pharm J (Ott). 2025 Jan 8;158(2):81-82.

Next Steps and Focus for the Next 6 Months:

- Update of epidemiology of hypertension in Canada based on new BP thresholds and targets provided by the 2025 clinical practice guidelines
- Assessment of hypertension awareness, treatment, and control in Canada pre- vs. post-COVID19 pandemic
- Assessment of hypertension screening results in the May Measurement Month 2025 campaign.
- Lead Canadian participation in the 2026 May Measurement Month campaign.





2025 FINANCIAL OVERVIEW

Hypertension Canada's fiscal year ended April 30, 2025, with the organization in a strong and stable financial position as reflected by a net operating profit of \$63,501 and an overall profit of just over \$302,000. This reflects a modest increase in overall association revenues, strong unrealized investment gains for the year, and significantly lower expenses associated with the absence of major in-person conference costs.

The audit for the 2025 fiscal year is complete, and we once again received an unqualified opinion on the financial statements with no unadjusted errors and only minimal and immaterial post-closing adjusting journal entries.

Total revenue for the year was \$503,141, an increase of approximately \$10,000 from the prior year, which was driven primarily by investment income and membership dues. Although revenues for the device endorsement and professional certification programs were each down slightly compared to the prior year, both programs remain a significant source of revenue with good potential for future growth.

Total expenses for the year were \$395,766, a 42% decrease from the previous year due to a virtual conference this year versus an in-person conference as noted above. Most other expense categories remained similar year-over-year.

The organization's balance sheet remained strong, with total assets of \$3.42 million at year-end, including \$3.24 million in investments. Net assets increased to \$3.37 million, up from \$3.07 million in the prior year, reflecting positive operational and investment performance.

In summary, our financial position remains strong, and we are pleased to be able to support the educational initiatives – such as Guidelines development and the planned 2026 Congress – that are vital to fulfilling our mission and vision.

Paul Braconnier
Treasurer

STAFF:

Please feel free to reach out to us if you ever have any questions or concerns



Maureen Melnyk
Executive Director
maureen.melnik@hypertension.ca



Cassandra Morin
Financial Manager
accounting@hypertension.ca





Sarah Goodyear
Coordinator
sarah.goodyear@hypertension.ca





Lindsay Nelson
Coordinator
lindsay.nelson@hypertension.ca

CONTACT:

 (905) 943-9400

 10547 114 Street
Edmonton AB T5H 3J6

 info@hypertension.ca

 <https://hypertension.ca/>